Mallinckrodt Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
ST. LOUIS--(BUSINESS WIRE)--Sep. 3, 2013--
(NYSE: MNK), a leading global specialty pharmaceuticals and global
medical imaging company, will present at the Morgan Stanley Global
Healthcare Conference in New York City on Monday, September 9, 2013.
Mark Trudeau, President and Chief Executive Officer of Mallinckrodt,
will represent the Company in a session scheduled to begin at 1:15 PM
A live audio webcast of the presentation can be accessed at
Mallinckrodt’s website, www.mallinckrodt.com,
in the Investor Relations tab.
Mallinckrodt is a leading global specialty pharmaceuticals business that
develops, manufactures, markets, and distributes specialty
pharmaceutical products and medical imaging agents. The Company’s
Specialty Pharmaceuticals segment includes branded and generic drugs,
and the Global Medical Imaging segment includes contrast media and
nuclear imaging agents. Mallinckrodt has approximately 5,500 employees
worldwide with direct sales in roughly 50 countries and distribution in
approximately 40 countries. The Company’s 2012 revenue totaled $2.1
billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
John Moten, 314-654-6650
Vice President, Investor
Manager, Media Relations
Senior Vice President, Communications